Clinical trial to examine the effectiveness of AMPA-PET to identify epileptogenic focus in refractory epilepsy patients

Phase 2

Recruiting

• Conditions: refractory epilepsy patients

• Registration Number: JPRN-jRCT1080224511
• Lead Sponsor: Tomoyuki Miyazaki (Coordinating Investigator)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-10
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

(1)refractory epilepsy patients
(2)patients who are planned to undergo lesionectomy
(3)patients who are without cerebral surgery
(4)patients who are 20 years or older
(5)patients who can consent to this study by oneself

Exclusion Criteria

(1)patients who have experienced the electric stimulation therapy
(2)patients who have severe kidney dysfunction within 7 days before 1st registration
(3)patients who have severe liver dysfunction within 7 days before 1st registration
(4)patients who should avoid from taking MRI or PET examination
(5)breast-feeding mothers, expecting mothers, females who desire to be a mother
(6)patients who desire to bear a child within this study period
(7)patients who take Fycompa or Topiramate within 4 weeks before 1st registration
(8)Patients who are suspected of severe alcohol sensitivity
(9)patients who have tumor suspected to be epileptogenic before 1st registration
(10)patients who underwent unapproved nuclear medicine examination within 24 weeks before 1st registration
(11)patients who underwent other clinical trials within 12 weeks before 1st registration
(12)patients who have uncontrollable diabetes
(13)patients whom study doctors consider unappropriated

Study & Design

• Study Type: Interventional
• Study Design: Not specified